Thakkar Roopal (CIK 2004979) reported 14 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-03-03). Recent activity: Sell ABBV (8,037 shares), Buy ABBV (6,015 shares), Buy ABBV (2,138 shares), Buy ABBV (3,346 shares), Buy ABBV (6,638 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-03 | AbbVie Inc. (ABBV) | EVP, R&D and CSO | Sell | 8,037 | $1.9M |
| 2026-02-20 | AbbVie Inc. (ABBV) | EVP, R&D and CSO | Buy | 6,015 | $0 |
| 2026-02-20 | AbbVie Inc. (ABBV) | EVP, R&D and CSO | Buy | 2,138 | $0 |
| 2026-02-20 | AbbVie Inc. (ABBV) | EVP, R&D and CSO | Buy | 3,346 | $0 |
| 2026-02-20 | AbbVie Inc. (ABBV) | EVP, R&D and CSO | Buy | 6,638 | $0 |
| 2025-03-04 | AbbVie Inc. (ABBV) | EVP, R&D and CSO | Sell | 4,678 | $959,084 |
| 2025-02-18 | AbbVie Inc. (ABBV) | EVP, R&D and CSO | Buy | 3,595 | $0 |
| 2025-02-18 | AbbVie Inc. (ABBV) | EVP, R&D and CSO | Buy | 1,474 | $0 |
| 2025-02-18 | AbbVie Inc. (ABBV) | EVP, R&D and CSO | Buy | 2,138 | $0 |
| 2025-02-18 | AbbVie Inc. (ABBV) | EVP, R&D and CSO | Buy | 3,348 | $0 |
| 2025-02-07 | AbbVie Inc. (ABBV) | EVP, R&D and CSO | Buy | 5,900 | $0 |
| 2025-02-07 | AbbVie Inc. (ABBV) | EVP, R&D and CSO | Buy | 1,572 | $0 |
| 2025-02-07 | AbbVie Inc. (ABBV) | EVP, R&D and CSO | Buy | 1,476 | $0 |
| 2025-02-07 | AbbVie Inc. (ABBV) | EVP, R&D and CSO | Buy | 2,140 | $0 |
Source: SEC Form 4 filings · as of 2026-03-03